180 related articles for article (PubMed ID: 35895438)
1. Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients.
Henriksen TV; Reinert T; Rasmussen MH; Demuth C; Løve US; Madsen AH; Gotschalck KA; Iversen LH; Andersen CL
Mol Oncol; 2022 Oct; 16(20):3654-3665. PubMed ID: 35895438
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort.
Henriksen TV; Demuth C; Frydendahl A; Nors J; Nesic M; Rasmussen MH; Reinert T; Larsen OH; Jaensch C; Løve US; Andersen PV; Kolbro T; Thorlacius-Ussing O; Monti A; Gögenur M; Kildsig J; Bondeven P; Schlesinger NH; Iversen LH; Gotschalck KA; Andersen CL
Ann Oncol; 2024 Feb; 35(2):229-239. PubMed ID: 37992872
[TBL] [Abstract][Full Text] [Related]
3. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study.
Øgaard N; Reinert T; Henriksen TV; Frydendahl A; Aagaard E; Ørntoft MW; Larsen MØ; Knudsen AR; Mortensen FV; Andersen CL
Eur J Cancer; 2022 Mar; 163():163-176. PubMed ID: 35074652
[TBL] [Abstract][Full Text] [Related]
4. Locally performed postoperative circulating tumour DNA testing performed during routine clinical care to predict recurrence of colorectal cancer.
Cohen R; Beasley A; McCoy M; Platell C; Meehan K; Gray E; Fuller K
ANZ J Surg; 2023 Oct; 93(10):2473-2480. PubMed ID: 36921099
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
7. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations.
Wong R; Tie J; Lee M; Cohen J; Wang Y; Li L; Ma S; Christie M; Kosmider S; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2019 Jul; 145(2):540-547. PubMed ID: 30628066
[TBL] [Abstract][Full Text] [Related]
8. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer.
Chen G; Peng J; Xiao Q; Wu HX; Wu X; Wang F; Li L; Ding P; Zhao Q; Li Y; Wang D; Shao Y; Bao H; Pan Z; Ding KF; Cai S; Wang F; Xu RH
J Hematol Oncol; 2021 May; 14(1):80. PubMed ID: 34001194
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
10. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
[TBL] [Abstract][Full Text] [Related]
12. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
15. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
Adams AM; Vreeland TJ; Newhook TE
J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of circulating tumour DNA in colorectal cancer.
Loft M; To YH; Gibbs P; Tie J
Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):837-852. PubMed ID: 37499673
[TBL] [Abstract][Full Text] [Related]
19. Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.
Ohta R; Yamada T; Sonoda H; Matsuda A; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yokoyama Y; Hara K; Yoshida H
Eur J Surg Oncol; 2021 Dec; 47(12):3151-3156. PubMed ID: 34315643
[TBL] [Abstract][Full Text] [Related]
20. Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer.
Narayan RR; Goldman DA; Gonen M; Reichel J; Huberman KH; Raj S; Viale A; Kemeny NE; Allen PJ; Balachandran VP; D'Angelica MI; DeMatteo RP; Drebin JA; Jarnagin WR; Kingham TP
Ann Surg Oncol; 2019 Jun; 26(6):1824-1832. PubMed ID: 30706231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]